首页> 外文期刊>RNA & Disease >miR-126 and miR-223 as biomarkers of vascular damage in the course of Chronic Kidney Disease
【24h】

miR-126 and miR-223 as biomarkers of vascular damage in the course of Chronic Kidney Disease

机译:miR-126和miR-223是慢性肾脏病过程中血管损伤的生物标志物

获取原文
           

摘要

Development of disease is often due to deregulation of gene expression. The gene program is controlled at the post-transcriptional level by the action of small non-coding RNAs known as microRNAs (miRNAs), short, single-stranded molecules that control mRNA stability or translational repression via base pairing with regions in the 3' untranslated region of their target mRNAs. Over the last decade, considerable progress has been made to elucidate the roles of miRNAs in vascular pathogenesis and develop the use of miRNAs as innovative biomarkers in diagnostics, and as groundbreaking drugs in pharmacological treatments. It has been recently shown that several miRNAs are implicated in the course of chronic kidney disease (CKD) and are associated with vessel damage, such as vascular calcifications and atherosclerosis. The inflammatory miR-223 is increased in vitro in vascular smooth muscle cells subjected to uremic toxins and is also increased in vivo in more advanced stages of CKD. The endothelial-specific miR-126 is involved in vascular remodeling in response to laminar shear stress in HUVEC cells. Finally, miR-126 levels have been found to be deregulated in murine and human serum in the course of experimental CKD and in human diabetic patients. In conclusion, these miRNAs could play a role in CKD vascular remodeling and may therefore represent useful targets to prevent or treat complications of CKD.
机译:疾病的发展通常归因于基因表达的失调。基因程序通过称为microRNA(miRNA)的小型非编码RNA(通过与3'非翻译区的碱基配对来控制mRNA稳定性或翻译抑制的短单链分子)的作用在转录后水平进行控制。靶mRNA的区域。在过去的十年中,在阐明miRNA在血管发病机理中的作用以及开发miRNA作为诊断学中的创新生物标志物以及药理学治疗中的突破性药物方面已经取得了相当大的进步。最近已经显示,几种miRNA与慢性肾脏病(CKD)有关,并且与血管损伤例如血管钙化和动脉粥样硬化有关。在经受尿毒症毒素的血管平滑肌细胞中,炎症性miR-223在体外增加,而在CKD的更晚期阶段,炎症性miR-223在体内也增加。内皮特异性miR-126参与血管重塑,以响应HUVEC细胞中的层流切应力。最后,发现在实验性CKD过程中和人类糖尿病患者中,鼠和人血清中的miR-126水平失调。总之,这些miRNA可能在CKD血管重塑中发挥作用,因此可能代表了预防或治疗CKD并发症的有用靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号